Reporting of Perinatal Outcomes in Probiotic Randomized Controlled Trials. A Systematic Review and Meta-Analysis

The use of probiotic microorganisms in clinical practice has increased in recent years and a significant number of pregnant women are regular consumers of these products. However, probiotics might modulate the immune system, and whether or not this modulation is beneficial for perinatal outcomes is unclear. We performed a systematic review and meta-analysis to evaluate the reporting of perinatal outcomes in randomized controlled trials including women supplemented with probiotic microorganisms during pregnancy. We also analyzed the effects that the administration of probiotic microorganisms exerts on perinatal outcomes. In the review, 46 papers were included and 25 were meta-analyzed. Reporting of perinatal outcomes was highly inconsistent across the studies. Only birth weight, cesarean section, and weeks of gestation were reported in more than 50% of the studies. Random effects meta-analysis results showed that the administration of probiotic microorganisms during pregnancy did not have any a positive or negative impact on the perinatal outcomes evaluated. Subgroup analysis results at the strain level were not significantly different from main analysis results. The administration of probiotic microorganisms does not appear to influence perinatal outcomes. Nonetheless, future probiotic studies conducted in pregnant women should report probiotic strains and perinatal outcomes in order to shed light upon probiotics’ effects on pregnancy outcomes.Spanish Ministry of Science, Innovation, and Universities (Project FIS-ISCIII) P117/0230

Advanced hydrogels for treatment of diabetes

Diabetes mellitus is a chronic disease characterized by high levels of glucose in the blood, which leads to metabolic disorders with severe consequences. Today, there is no cure for diabetes. The current management for diabetes and derived medical conditions, such as hyperglycemia, cardiovascular diseases or diabetic foot ulcer, includes life style changes and hypoglycemia based therapy, which do not fully restore euglycemia or the functionality of damaged tissues in patients. This encourages scientists to work outside their boundaries to develop routes that can potentially tackle such metabolic disorders. In this regard, acellular and cellular approaches have represented an alternative for diabetics, although such treatments still face shortcomings related to limited effectiveness and immunogenicity. The advent of biomaterials has brought significant improvements for such approaches, and three-dimensional extracellular matrix analogous, such as hydrogels, have played a key role in this regard. Advanced hydrogels are being developed to monitor high blood glucose levels and release insulin, as well as serve as a therapeutic technology. Herein, the state of the art in advanced hydrogels for improving treatment of diabetes, from laboratory technology to commercial products approved by drug safety regulatory authorities, will be concisely summarized and discussed. [Abstract copyright: This article is protected by copyright. All rights reserved.

Assessing the Suitability of King Topologies for Interconnection Networks

In the late years many different interconnection networks have been used with two main tendencies. One is characterized by the use of high-degree routers with long wires while the other uses routers of much smaller degree. The latter rely on two-dimensional mesh and torus topologies with shorter local links. This paper focuses on doubling the degree of common 2D meshes and tori while still preserving an attractive layout for VLSI design. By adding a set of diagonal links in one direction, diagonal networks are obtained. By adding a second set of links, networks of degree eight are built, named king networks. This research presents a comprehensive study of these networks which includes a topological analysis, the proposal of appropriate routing procedures and an empirical evaluation. King networks exhibit a number of attractive characteristics which translate to reduced execution times of parallel applications. For example, the execution times NPB suite are reduced up to a 30 percent. In addition, this work reveals other properties of king networks such as perfect partitioning that deserves further attention for its convenient exploitation in forthcoming high-performance parallel systems

Milk yield and milk fatty acids from crossbred F1 dairy cows fed on tropical grasses and supplemented with different levels of concentrate

The objective of this study was to determine milk fatty acids from crossbred F1 dairy cows fed on tropical grasses and supplemented with different levels of concentrate. Twelve dairy cows (50% Holstein x 50% Brahman) with 60 days of lactation grazing tropical grasses were assigned to a Switchback design, with three periods of 15 days with different concentrate levels: 0, 150, 300 and 450 g /kg. Milk samples were obtained on the last five days of each experimental period. Milk yield and milk composition were not affected. Cows fed with 300 g/kg of concentrate had higher contents of C15:0 (p = 0.004), C22:0 (p = 0.031), and C24:0 (p = 0.013). C17:1 cis9 was higher (p = 0.039) with 150 g/kg and lowest with 450 g/kg. C18:1 cis9 was higher (p = 0.042) with 150 g/kg. C18:2n6trans was higher (p = 0.05) with 300 g/kg and lower (p = 0.018) with 450 g/kg. This study shows that adding up to 450 g/kg of concentrate to crossbred F1 dairy cows fed on tropical grasses does not have negative effects on milk yield and milk quality. Therefore, under these production conditions, farmers can rely on tropical grasses and reduce feeding costs

CATA: Criticality aware task acceleration for multicore processors

Managing criticality in task-based programming models opens a wide range of performance and power optimization opportunities in future manycore systems. Criticality aware task schedulers can benefit from these opportunities by scheduling tasks to the most appropriate cores. However, these schedulers may suffer from priority inversion and static binding problems that limit their expected improvements. Based on the observation that task criticality information can be exploited to drive hardware reconfigurations, we propose a Criticality Aware Task Acceleration (CATA) mechanism that dynamically adapts the computational power of a task depending on its criticality. As a result, CATA achieves significant improvements over a baseline static scheduler, reaching average improvements up to 18.4% in execution time and 30.1% in Energy-Delay Product (EDP) on a simulated 32-core system. The cost of reconfiguring hardware by means of a software-only solution rises with the number of cores due to lock contention and reconfiguration overhead. Therefore, novel architectural support is proposed to eliminate these overheads on future manycore systems. This architectural support minimally extends hardware structures already present in current processors, which allows further improvements in performance with negligible overhead. As a consequence, average improvements of up to 20.4% in execution time and 34.0% in EDP are obtained, outperforming state-of-the-art acceleration proposals not aware of task criticality.This work has been supported by the Spanish Government (grant SEV2015-0493, SEV-2011-00067 of the Severo Ochoa Program), by the Spanish Ministry of Science and Innovation (contracts TIN2015-65316, TIN2012-34557, TIN2013-46957-C2-2-P), by Generalitat de Catalunya (contracts 2014-SGR- 1051 and 2014-SGR-1272), by the RoMoL ERC Advanced Grant (GA 321253) and the European HiPEAC Network of Excellence. The Mont-Blanc project receives funding from the EU’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no 610402 and from the EU’s H2020 Framework Programme (H2020/2014-2020) under grant agreement no 671697. M. Moret´o has been partially supported by the Ministry of Economy and Competitiveness under Juan de la Cierva postdoctoral fellowship number JCI-2012-15047. M. Casas is supported by the Secretary for Universities and Research of the Ministry of Economy and Knowledge of the Government of Catalonia and the Cofund programme of the Marie Curie Actions of the 7th R&D Framework Programme of the European Union (Contract 2013 BP B 00243). E. Castillo has been partially supported by the Spanish Ministry of Education, Culture and Sports under grant FPU2012/2254.Peer ReviewedPostprint (author's final draft

Physicochemical Characteristics of Transferonƒ Batches

Transferon, a biotherapeutic agent that has been used for the past 2 decades for diseases with an inflammatory component, has been approved by regulatory authorities in Mexico (COFEPRIS) for the treatment of patients with herpes infection. The active pharmaceutical ingredient (API) of Transferon is based on polydispersion of peptides that have been extracted from lysed human leukocytes by a dialysis process and a subsequent ultrafiltration step to select molecules below 10 kDa. To physicochemically characterize the drug product, we developed chromatographic methods and an SDS-PAGE approach to analyze the composition and the overall variability of Transferon. Reversed-phase chromatographic profiles of peptide populations demonstrated batch-tobatch consistency from 10 representative batches that harbored 4 primary peaks with a relative standard deviation (RSD) of less than 7%. Aminogram profiles exhibited 17 proteinogenic amino acids and showed that glycine was the most abundant amino acid, with a relative content of approximately 18%. Further, based on their electrophoretic migration, the peptide populations exhibited a molecular mass of about 10 kDa. Finally, we determined the Transferon fingerprint using a mass spectrometry tool. Because each batch was produced from independent pooled buffy coat samples from healthy donors, supplied by a local blood bank, our results support the consistency of the production of Transferon and reveal its peptide identity with regard to its physicochemical attributes

Revisiting the epidemiology of bloodstream infections and healthcare-associated episodes: results from a multicentre prospective cohort in Spain (PRO-BAC Study)

PROBAC REIPI/GEIH-SEIMC/SAEI Group.The epidemiology of bloodstream infections (BSIs) is dynamic as it depends on microbiological, host and healthcare system factors. The aim of this study was to update the information regarding the epidemiology of BSIs in Spain considering the type of acquisition. An observational, prospective cohort study in 26 Spanish hospitals from October 2016 through March 2017 including all episodes of BSI in adults was performed. Bivariate analyses stratified by type of acquisition were performed. Multivariate analyses were performed by logistic regression. Overall, 6345 BSI episodes were included; 2510 (39.8%) were community-acquired (CA), 1661 (26.3%) were healthcare-associated (HCA) and 2056 (32.6%) hospital-acquired (HA). The 30-day mortality rates were 11.6%, 19.5% and 22.0%, respectively. The median age of patients was 71 years (interquartile range 60–81 years) and 3656 (58.3%; 95% confidence interval 57.1–59.6%) occurred in males. The proportions according to patient sex varied according to age strata. Escherichia coli (43.8%), Klebsiella spp. (8.9%), Staphylococcus aureus (8.9%) and coagulase-negative staphylococci (7.4%) were the most frequent pathogens. Multivariate analyses confirmed important differences between CA and HCA episodes, but also between HCA and HA episodes, in demographics, underlying conditions and aetiology. In conclusion, we have updated the epidemiological information regarding patients’ profiles, underlying conditions, frequency of acquisition types and aetiological agents of BSI in Spain. HCA is confirmed as a distinct type of acquisition.This work was financed by grants from Plan Nacional de I+D+i 2013–2016, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades [PI16/01432] and the Spanish Network for Research in Infectious Diseases (REIPI) [RD16/0016/0001; RD16/0016/0008], co‐financed by the European Development Regional Fund ‘A way to achieve Europe’, Operative program Intelligent Growth 2014–2020